it was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial.  A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking it.  The drug was also evaluated in the treatment of retinal detachment and other diseases of the retina.  it has not gained FDA approval, and clinical trials with this drug have ceased since 2011. 
